As of Nov. 17, 2025 two healthcare stocks—Avadel Pharmaceuticals (RSI 95.1) and Cidara Therapeutics (RSI 93.7)—are flagged as heavily overbought after deal-driven rallies. Avadel jumped 22.5% to $23.56 following an unsolicited Lundbeck proposal valuing the company at up to $23 per share ($21 cash plus up to $2 in CVRs) and has gained roughly 55% over the past month; Cidara rose 105.4% to $217.71 after Merck agreed to acquire it for $221.50 per share in a transaction worth about $9.2 billion, pushing its one‑month gain to roughly 114%. The readings—well above the common 70 overbought threshold—suggest elevated short‑term pullback risk for momentum-focused investors despite the clear M&A catalysts.
Two healthcare names are exhibiting extreme short-term momentum after M&A-driven rallies: Avadel Pharmaceuticals (AVDL) and Cidara Therapeutics (CDTX). Avadel’s RSI is 95.1 after a roughly 55% one‑month gain and a 22.5% jump to $23.56 on Nov. 14 following an unsolicited Lundbeck proposal valuing the company at up to $23 per share ($21 cash plus up to $2 in CVRs); its 52‑week high is $23.57. Cidara’s RSI is 93.7 after a roughly 114% one‑month gain and a 105.4% rise to $217.71 on Nov. 14 after Merck agreed to acquire the company for $221.50 per share in a transaction valued at about $9.2 billion; its 52‑week high is $218.85. RSI readings well above the customary 70 overbought threshold signal elevated short‑term mean‑reversion risk despite clear deal catalysts; Avadel also shows a very high Momentum score (96.26) but low Value (4.05), underscoring technical overextension. The Merck bid for Cidara creates a near‑definitive event with a narrow gap to the offer price, reducing open equity risk to deal close but leaving regulatory and closing risk. By contrast, Avadel’s unsolicited proposal leaves material execution uncertainty—either competing bids or deal failure would materially change valuation and price direction. Investors should therefore treat the two situations differently: Cidara is primarily an event/arbitrage story with limited upside beyond the deal price and exposure to closing risk, while Avadel remains a binary takeover story with significant downside if the proposal does not firm or is not increased. Monitor deal confirmations, regulatory commentary, trading volume and RSI reversion as the primary near‑term indicators of risk and timing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
0.03
Ticker Sentiment
